Boehringer Ingelheim
Global pharmaceutical company using AI single-cell and protein-engineering platforms for target discovery and antibody optimization in oncology and immunology.
- Company type
- Global pharmaceutical company
- Headquarters
- Ingelheim am Rhein, Germany
- Website
- https://www.boehringer-ingelheim.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2026-06-25 — T-cell target-discovery deal with Immunai (Immunai). Boehringer Ingelheim agreed to pay as much as $15 million to discover new targets on dysfunctional T cells driving cancers and autoimmune diseases, using Immunai's single-cell AI platform. The deal extends through 2027 with the option to expand. Disclosed: Up to $15M. Source: Fierce Biotech (accessed 2026-07-29)
- 2026-03-31 — Expanded antibody-discovery partnership with OpenProtein.AI (OpenProtein.AI). Following a successful initial deployment in 2025, Boehringer Ingelheim expanded its partnership with OpenProtein.AI to co-develop specialized antibody discovery and optimization workflows, integrating OpenProtein.AI's foundation models and cloud platform into its therapeutic-development processes. Financial terms were not disclosed. Source: PR Newswire (OpenProtein.AI release) (accessed 2026-07-29)